Close Menu

Waters

Among the launches at the organization's annual meeting this week in Taipei were a personalized proteomics initiative and a new DIA mass spec method.

The company posted Q2 revenues of $536.6 million, up from $494.7 million in Q2 2015 and beating the average Wall Street estimate of $523.4 million.

The mass spectrometry instrument maker will provide A*Star's Bioprocessing Technology Institute with expertise and access to a Synapt G2-S instrument.

While most firms launched new mass spec systems, the larger focus was on developing and implementing the larger workflows surrounding these instruments.

Along with scientists from the University of Leicester, the researchers picked the Xevo TQ-S micro platform to do a pilot study on heart failure patient samples.

The firm sold three series of senior notes and will use proceeds to repay other outstanding debt.

Driven by strong pharma demand, the company posted first quarter revenues of $475.2 million, beating the average Wall Street estimate of $472.2 million.

The company said that it acquired Nottingham, UK-based Midland in order to lower its future manufacturing expenses and reduce risk to its supply chain.

Revenues were up to $587 million in the quarter, compared to $584 million in Q4 2014. Foreign currency effects reduced Q4 2015 revenues by around 5 percent.

The investment bank also initiated coverage of Agilent Technologies, Bruker, Illumina, PerkinElmer, and Waters with a Hold rating.

Pages

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.